TACT411

TACT411 is a monoamine transporter modulator and serotonin 5-HT_1B receptor modulator which is under development for the treatment of alcohol use disorder, anorexia, and binge-eating disorder.^[1][2] It is being developed by Tactogen.^[1][2] As of the first quarter of 2025, the drug is in the preclinical research stage of development.^[1][2]

TACT411

Clinical data
Other names	TACT-411
Drug class	Monoamine transporter modulator; Serotonin 5-HT1B receptor modulator

See also

• TACT833
• TACT908
• 1Z2MAP1O
• List of investigational hallucinogens and entactogens